Eye Affecting Patents (Class 514/20.8)
-
Publication number: 20150094260Abstract: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.Type: ApplicationFiled: August 14, 2014Publication date: April 2, 2015Inventors: Liora BRAIMAN-WIKSMAN, Yuval Sagiv, Ofra Levy-Hacham, Tamar Tennenbaum
-
Publication number: 20150079179Abstract: The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided.Type: ApplicationFiled: September 15, 2014Publication date: March 19, 2015Inventor: Gary P. COOK
-
Publication number: 20150079094Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.Type: ApplicationFiled: September 12, 2014Publication date: March 19, 2015Inventors: Joyce Tombran-Tink, Colin J. Barnstable
-
Publication number: 20150071877Abstract: A method for preparing a bioactive composition containing conditioned cell culture medium is disclosed. The method comprises culturing cells of two or more eukaryotic cell line to form conditioned culture media, separating the cultured cells from the conditioned culture media, and combining conditioned culture media to form a bioactive composition. Novel bioactive compositions, formulations and their use in treating of a variety of diseases and health conditions are also disclosed.Type: ApplicationFiled: November 12, 2014Publication date: March 12, 2015Inventors: Greg Maguire, Peter Friedman
-
Patent number: 8975229Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.Type: GrantFiled: June 10, 2010Date of Patent: March 10, 2015Assignee: OncoTherapy Science, Inc.Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda
-
Patent number: 8969306Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.Type: GrantFiled: September 13, 2013Date of Patent: March 3, 2015Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 8962567Abstract: Disclosed is a treatment for ophthalmic diseases, more specifically, a pharmaceutical composition for treating ophthalmic diseases including a fusion protein of FK506 binding protein capable of penetrating into the ocular tissue as an active ingredient.Type: GrantFiled: April 6, 2011Date of Patent: February 24, 2015Assignee: Industry Academic Cooperation Foundation, Hallym UniversityInventors: Soo Young Choi, Dae Won Kim, Sung Ho Lee, Jinseu Park, Won Sik Eum
-
Patent number: 8957043Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.Type: GrantFiled: June 4, 2013Date of Patent: February 17, 2015Assignees: Novartis AG, Universite de StrasbourgInventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
-
Publication number: 20150044181Abstract: The invention provides compositions and kits including at least one nucleic acid or polypeptide molecule encoding for a mutant ChR2 protein. Methods of the invention include administering a composition comprising a mutant ChR2 to a subject to preserve, improve, or restore phototransduction. Preferably, the compositions and methods of the invention are provided to a subject having impaired vision, thereby restoring vision to normal levels.Type: ApplicationFiled: March 5, 2013Publication date: February 12, 2015Inventor: Zhuo-hua Pan
-
Publication number: 20150045296Abstract: Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.Type: ApplicationFiled: March 15, 2013Publication date: February 12, 2015Applicant: XAVIER UNIVERSITY OF LOUISIANAInventor: Partha S. Bhattacharjee
-
Publication number: 20150045302Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.Type: ApplicationFiled: March 14, 2013Publication date: February 12, 2015Inventors: Angelo Corti, Flavio Curnis
-
Publication number: 20150037350Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.Type: ApplicationFiled: March 15, 2013Publication date: February 5, 2015Applicant: UCL BUSINESS PLCInventors: Anna L. Furmanski, Jose Ignacio Saldana, Tessa Crompton
-
Publication number: 20150038432Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.Type: ApplicationFiled: February 25, 2013Publication date: February 5, 2015Applicant: UNIVERSITE DE STRASBOURGInventors: Vincent Marion, Anaïs Mockel, Hélène Dollfus
-
Publication number: 20150038433Abstract: Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.Type: ApplicationFiled: August 29, 2014Publication date: February 5, 2015Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: M. Elizabeth Fini, Shinwu JEONG
-
Patent number: 8946170Abstract: An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer is described. The biocompatible polymer comprises a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.Type: GrantFiled: July 20, 2011Date of Patent: February 3, 2015Assignee: Allergan, Inc.Inventors: Hongwen M. Rivers, Lon T. Spada, Michelle Luu
-
Patent number: 8945602Abstract: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.Type: GrantFiled: March 29, 2013Date of Patent: February 3, 2015Assignee: The Regents of the University of CaliforniaInventors: William Freeman, Michael J. Sailor, Lingyun Cheng, Frederique Cunin, Emily Anglin, Yang Yang Li
-
Publication number: 20150031629Abstract: An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein. The aqueous solution comprises from about 0.01% by weight to about 30% by weight of the silk protein. In one embodiment, the silk protein may be fibroin. A method of treating an eye having an ocular surface is also described. The method comprises providing an ophthalmic composition comprising an aqueous solution including an effective amount of silk protein, and administering the ophthalmic composition topically to the ocular surface.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Applicant: SilkTears, Inc.Inventors: Brian Lawrence, Jon St. Germain
-
Patent number: 8940702Abstract: The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.Type: GrantFiled: July 26, 2010Date of Patent: January 27, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de BordeauxInventors: Andreas Bikfalvi, Herve Prats, Cathy Quemener, Alexandre Dubrac
-
Publication number: 20150018267Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory AgentType: ApplicationFiled: August 6, 2012Publication date: January 15, 2015Applicant: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.Inventors: Patricia A. D'Amore, Pablo Argüeso, Alisar S. Zahr
-
Publication number: 20150018287Abstract: An eye drop containing (i) a peptide having an amino acid sequence which is represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmaceutically acceptable salt thereof and (ii) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmaceutically acceptable salt thereof. The concentration ratio of the SSSR or a pharmaceutically acceptable salt thereof and the FGLM or a pharmaceutically acceptable salt thereof is 1/15 and 1/50. The concentration of the SSSR or a pharmaceutically acceptable salt thereof is 0.001% to 0.3% (w/v), and the concentration of the FGLM or a pharmaceutically acceptable salt thereof is 0.015% to 1.5% (w/v). The pH of the eye drop is 2.5 to 6.5. The eye drop serves to minimize the occurrence of side effects and serves to improve its storage stability.Type: ApplicationFiled: July 18, 2014Publication date: January 15, 2015Inventors: Takahiro NAKAMURA, Yuichiro NAKADA, Takashi NAGANO, Masatsugu NAKAMURA
-
Publication number: 20150018288Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 21, 2013Publication date: January 15, 2015Applicant: Stealth Peptides International, Inc.Inventors: D. Travis Wilson, K. George Mooney, Peter J. Oates
-
Patent number: 8933031Abstract: Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis.Type: GrantFiled: February 4, 2008Date of Patent: January 13, 2015Assignee: Shanghai First People's HospitalInventors: Hui Zhao, Xun Xu
-
Publication number: 20150011474Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX23X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.Type: ApplicationFiled: February 19, 2013Publication date: January 8, 2015Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 8927232Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.Type: GrantFiled: December 11, 2009Date of Patent: January 6, 2015Assignee: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
-
Publication number: 20150005228Abstract: Disclosed is the method of treating keratits in a subject thereof comprising administering into the subject an amphiphilic peptides of the present disclosure. Also disclosed are methods of removing biofilm from cornea.Type: ApplicationFiled: July 1, 2014Publication date: January 1, 2015Inventors: Yi-Yan Yang, Zhan Yuin Ong
-
Publication number: 20150004165Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: September 8, 2014Publication date: January 1, 2015Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
-
Publication number: 20150005239Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.Type: ApplicationFiled: June 11, 2014Publication date: January 1, 2015Inventors: Pablo VILLOSLADA, Angel Messeguer
-
Publication number: 20140378372Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.Type: ApplicationFiled: January 7, 2013Publication date: December 25, 2014Inventors: Soren Mogelsvang, Cohava Gelber
-
Patent number: 8916517Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: GrantFiled: November 2, 2010Date of Patent: December 23, 2014Assignee: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jerome L. Maderdrut, Min Li
-
Publication number: 20140369997Abstract: The present application describes a method of creating a foaming ophthalmic formulation. The described formulation includes the addition of a foaming agent. The resulting solution is designed to be distributed by a non-aerosol foaming bottle/or aerosol.Type: ApplicationFiled: February 2, 2012Publication date: December 18, 2014Applicant: PASEInventor: Calvin Alexander Grant
-
Publication number: 20140371161Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.Type: ApplicationFiled: January 16, 2013Publication date: December 18, 2014Applicant: Governing Council of The University of TorontoInventor: Paulo Koeberle
-
Patent number: 8911768Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.Type: GrantFiled: June 17, 2014Date of Patent: December 16, 2014Assignee: Allergan, Inc.Inventors: Scott M. Whitcup, David A. Weber
-
Publication number: 20140364379Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.Type: ApplicationFiled: July 26, 2012Publication date: December 11, 2014Applicant: Allergan Inc.Inventors: Anuradha V. Gore, Sai Shankar, Sukhon Likitiersuang, Chetan P. Pujara, Sesha Neervanna
-
Patent number: 8906852Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.Type: GrantFiled: April 8, 2011Date of Patent: December 9, 2014Assignee: MethylGene Inc.Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frédéric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
-
Patent number: 8906861Abstract: A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.Type: GrantFiled: January 28, 2009Date of Patent: December 9, 2014Assignee: Allergan, Inc.Inventors: Walter L. Tien, Richard S. Graham, James N. Chang
-
Publication number: 20140341932Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.Type: ApplicationFiled: May 14, 2014Publication date: November 20, 2014Inventors: Anthony Robert Milnes Coates, Peter Tormay, Andrew Lightfoot
-
Publication number: 20140336108Abstract: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: Xialing Guo, Zhen Zhu
-
Publication number: 20140336126Abstract: The invention relates to Optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in SEQ ID no2, which represents the portion of the wild-type human Optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in SEQ ID no2, or having a polypeptidic sequence derived from the polypeptidic sequence disclosed in SEQ ID no2 to the exclusion of the wild-type Optineurin protein. The polypeptide(s) of the invention retain one, any combination of two, or three of the following functional properties: the capacity to bind Rab8 protein, when the latter are associated with the Golgi apparatus of a cell, the capacity to bind MYPT1 protein, when said protein is engaged in a Myosin-Phosphatase (MP) complex, the capacity to be phosphorylated by Plk1.Type: ApplicationFiled: December 18, 2012Publication date: November 13, 2014Inventors: Robert Serge Weil, David Kachaner, Josina Côrte-Real Filipe, Emmanuel François Laplantine, Alain Israël
-
Publication number: 20140335078Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9.Type: ApplicationFiled: May 6, 2014Publication date: November 13, 2014Applicant: Genentech, Inc.Inventors: Sek Chung Fung, Zhengbin Yao
-
Patent number: 8883738Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.Type: GrantFiled: December 13, 2012Date of Patent: November 11, 2014Assignee: Karisruher Insitut für TechnologieInventors: Alexandra Matzke, Helmut Ponta, Véronique Orian-Rousseau, Martina Tremmel
-
Patent number: 8883965Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: GrantFiled: February 5, 2007Date of Patent: November 11, 2014Assignee: Ferring B.V.Inventors: Kazimierz Wisniewski, Robert Felix Galyean
-
Publication number: 20140328894Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.Type: ApplicationFiled: July 16, 2014Publication date: November 6, 2014Inventors: Eugene de Juan, JR., Cary Reich, Stephen Boyd, Hanson S. Gifford, Mark Deem
-
Publication number: 20140322302Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: May 11, 2014Publication date: October 30, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20140315787Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20140315806Abstract: The present invention relates to veterinary decorin compositions and methods of their production.Type: ApplicationFiled: April 22, 2014Publication date: October 23, 2014Applicant: CATALENT PHARMA SOLUTIONS, LLCInventor: Gregory T. Bleck
-
Patent number: 8865654Abstract: An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3% (w/v) and the concentration of FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drop is maintained between 2.5 and 6.5.Type: GrantFiled: September 24, 2010Date of Patent: October 21, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Takahiro Nakamura, Yuichiro Nakada, Takashi Nagano, Masatsugu Nakamura
-
Patent number: 8858943Abstract: The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with antigen binding proteins that bind ?-amyloid peptide and in particular human ?-amyloid peptide.Type: GrantFiled: September 23, 2008Date of Patent: October 14, 2014Assignee: Glaxo Group LimitedInventors: Stephen Anthony Burbidge, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
-
Publication number: 20140303080Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Publication number: 20140302095Abstract: Provided herein are isolated polypeptides comprising the amino-terminal domain of Mycobacterium tuberculosis porin A (MtpA), wherein the polypeptide is a porin monomer. Also provided are isolated polypeptides comprising the carboxy-terminal domain of Mycobacterium tuberculosis porin A, wherein the polypeptide is a toxin. Also provided are methods of treating or preventing a Mycobacterium tuberculosis (Mtb) infection in a subject with or at risk of developing a Mtb infection. Further provided are chimeric porin polypeptides comprising a first polypeptide comprising an amino-terminal domain of Mycobacterium tuberculosis porin and a second polypeptide comprising an antigen and the use the chimeric porin polypeptides in methods of eliciting an immune response in a subject.Type: ApplicationFiled: August 30, 2012Publication date: October 9, 2014Applicant: THE UAB RESEARCH FOUNDATIONInventors: Michael Niederweis, Olga Danilchanka
-
Publication number: 20140296159Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.Type: ApplicationFiled: May 8, 2014Publication date: October 2, 2014Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan